Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K. Tasian(Children's Hospital of Philadelphia), Stephan A. Grupp(Children's Hospital of Philadelphia)
Cited by 163
Related Papers
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
|Blood|2015|718
Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
|Journal of Clinical Investigation|2020|58